New 10% AEON (NYSE: AEON) owner holds warrants at $0.0001
Rhea-AI Filing Summary
AEON Biopharma, Inc. (AEON) disclosed the initial ownership of major shareholder Timothy P. Lynch on a Form 3. Lynch directly holds 5,350,000 shares of Class A Common Stock and derivative securities tied to additional shares. These include pre-funded warrants exercisable at $0.0001 per share for 1,000,000 underlying Class A shares that are exercisable at any time and have no expiration date.
He also holds two series of warrants, each covering 3,000,000 underlying Class A shares, with exercise prices of $0.3221 and $0.3704 per share. Certain warrants expire on the earlier of the second or fifth anniversary of issuance or 45 days after specified AEON FDA-related announcements. A 4.99% beneficial ownership limitation applies, which Lynch may adjust up to 19.99% with at least 61 days’ prior written notice, subject to the warrant terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
LYNCH TIMOTHY P
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Pre-Funded Warrants F1, F2 | -- | -- | -- |
| holding | Warrants F3, F4, F2 | -- | -- | -- |
| holding | Warrants F5, F6, F2 | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Pre-Funded Warrants — 1,000,000 shares (Direct);
Warrants — 6,000,000 shares (Direct);
Class A Common Stock — 5,350,000 shares (Direct)
Footnotes (6)
- F1. The pre-funded warrants are exercisable at any time and have no expiration date.
- F2. The reporting person (together with his affiliates) may not exercise any portion of these warrant to the extent that, after giving effect to such exercise, the reporting person would beneficially own more than 4.99% of the outstanding shares of Class A Common Stock immediately after exercise. The beneficial ownership limitation may be increased or decreased at the reporting person's election to a percentage not in excess of 19.99%, upon at least 61 days' prior written notice to us, subject to the terms of the warrants.
- F3. These warrants will expire on the earlier of (i) the second anniversary of the date of issuance and (ii) the 45th day following the Issuer's public announcement that it has received Type 2B meeting minutes from the FDA regarding certain matters.
- F4. At the option of the reporting person, each of these warrants may be exercised for either one share of Class A Common Stock or one pre-funded warrant to acquire Class A Common Stock.
- F5. These warrants will expire on the earlier of (i) the fifth anniversary of the date of issuance and (ii) 45 days following the Issuer's public announcement that the Issuer has initiated a Phase 3 clinical equivalence trial of ABP-450 as a biosimilar to BOTOX.
- F6. At the option of the reporting person, each of these warrants may be exercised for either one share of Class A Common Stock or one pre-funded warrant to acquire Class A Common Stock.
Key Figures
Directly held Class A Common Stock: 5,350,000 shares
Pre-Funded Warrants underlying shares: 1,000,000 shares
Pre-Funded Warrants exercise price: $0.0001 per share
+5 more
8 metrics
Directly held Class A Common Stock
5,350,000 shares
Total shares of Class A Common Stock held directly following the reported holdings
Pre-Funded Warrants underlying shares
1,000,000 shares
Underlying Class A Common Stock for pre-funded warrants at $0.0001 exercise price
Pre-Funded Warrants exercise price
$0.0001 per share
Exercise price for pre-funded warrants with no expiration date
First Warrant Series exercise price
$0.3221 per share
Exercise price for warrants covering 3,000,000 underlying Class A shares
Second Warrant Series exercise price
$0.3704 per share
Exercise price for warrants covering 3,000,000 underlying Class A shares
Beneficial ownership limitation
4.99%
Initial cap on beneficial ownership after exercise of certain warrants
Maximum adjustable ownership cap
19.99%
Highest beneficial ownership limitation allowed upon election with 61 days’ notice
Notice period to change ownership cap
61 days
Minimum prior written notice required to adjust the beneficial ownership limitation
Key Terms
Pre-Funded Warrants, beneficial ownership limitation, Type 2B meeting minutes, Phase 3 clinical equivalence trial, +1 more
5 terms
Pre-Funded Warrants financial
"The pre-funded warrants are exercisable at any time and have no expiration date"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership limitation regulatory
"may not exercise any portion of these warrant to the extent that, after giving"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Type 2B meeting minutes medical
"45th day following the Issuer's public announcement that it has received Type 2B"
Phase 3 clinical equivalence trial medical
"45 days following the Issuer's public announcement that the Issuer has initiated a Phase 3"
biosimilar medical
"clinical equivalence trial of ABP-450 as a biosimilar to BOTOX"
A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.
FAQ
What did AEON (AEON) disclose about Timothy P. Lynch in this Form 3?
AEON reported that Timothy P. Lynch is a ten percent owner holding 5,350,000 shares of Class A Common Stock plus several warrant positions for additional shares, all held directly as of the reporting date.
What pre-funded warrants in AEON (AEON) does Timothy P. Lynch hold?
He holds pre-funded warrants with an exercise price of $0.0001 per share for 1,000,000 underlying AEON Class A shares. These pre-funded warrants are exercisable at any time and have no expiration date.
What other warrant positions in AEON (AEON) are reported for Timothy P. Lynch?
Lynch holds two additional warrant series, each exercisable into 3,000,000 AEON Class A shares, with exercise prices of $0.3221 and $0.3704 per share, subject to specific expiration triggers tied to anniversaries and FDA-related milestones.
What is the beneficial ownership limitation on Timothy P. Lynch’s AEON (AEON) warrants?
The warrants include a 4.99% beneficial ownership limitation after exercise. Lynch may elect to change this cap to a percentage not exceeding 19.99% by giving at least 61 days’ prior written notice, subject to the warrant terms.
Do any of Timothy P. Lynch’s AEON (AEON) warrants have milestone-based expirations?
Yes. Certain warrants expire on the earlier of the second or fifth anniversary of issuance or 45 days after AEON publicly announces specified FDA-related events, such as Type 2B meeting minutes or initiation of a Phase 3 clinical equivalence trial.
AI-generated analysis. How Rhea-AI works. Not financial advice.
